A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Status: | Completed |
---|---|
Conditions: | Cancer, Cancer, Pancreatic Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 9/20/2018 |
Start Date: | May 2015 |
End Date: | August 2018 |
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
The purpose of this study is to determine whether the combination of MM-141 plus
nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone
based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients
with high serum levels of free IGF-1.
nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone
based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients
with high serum levels of free IGF-1.
This is a randomized, double-blind, placebo-controlled Phase 2 study of MM-141 plus
nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine in front-line
metastatic pancreatic cancer. All patients will be initially screened for free IGF-1 status.
Eligible patients with high free IGF-1 will be randomized to receive MM-141 plus
nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine and patients.
Patients with low free IGF-1 or patients who have high free IGF-1 but are not otherwise
eligible will be followed in an observational group.
nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine in front-line
metastatic pancreatic cancer. All patients will be initially screened for free IGF-1 status.
Eligible patients with high free IGF-1 will be randomized to receive MM-141 plus
nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine and patients.
Patients with low free IGF-1 or patients who have high free IGF-1 but are not otherwise
eligible will be followed in an observational group.
Inclusion Criteria:
- Metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not
eligible.
- Patient must have received no prior radiotherapy, surgery, chemotherapy, or
investigational therapy for the treatment of metastatic disease.
- Blood sample sent for free IGF-1 testing
- ECOG performance status (PS) of 0 or 1
Exclusion Criteria:
- Patients who only present with localized disease
- Patients with CNS malignancies (primary or metastatic)
- Clinically significant cardiac disease
We found this trial at
48
sites
Philadelphia, Pennsylvania 19111
Principal Investigator: Crystal Denlinger, MD
Phone: 215-214-1685
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Emily Chan, MD
Phone: 615-875-0060
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
New York, New York 10027
(212) 854-1754
Principal Investigator: Paul Oberstein, MD
Phone: 212-342-0248
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Bethlehem, Pennsylvania
Principal Investigator: Asim Ali, MD
Phone: 484-526-3589
Click here to add this to my saved trials
Buffalo, New York 14263
Principal Investigator: Wen Wee Ma, MD
Phone: 716-845-8309
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Halla Nimeiri, MD
Phone: 312-695-1102
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
Chicago, Illinois
(312) 996-4350
Principal Investigator: Arkadiusz Dudek, MD
Phone: 312-413-1902
University of Illinois at Chicago A major research university in the heart of one of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
East Setauket, New York 11733
Principal Investigator: David Chu, MD
Phone: 631-675-5143
Click here to add this to my saved trials
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
Fairfax, Virginia 22031
(703) 280-5390
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
Click here to add this to my saved trials
Click here to add this to my saved trials
Fullerton, California 92835
Principal Investigator: David Park, MD
Phone: 714-446-5364
Click here to add this to my saved trials
Gilbert, Arizona 85234
Principal Investigator: Madappa N. Kundranda, MD
Phone: 480-256-4649
Click here to add this to my saved trials
Click here to add this to my saved trials
Lafayette, Louisiana 70503
Principal Investigator: Salman Malad, MD
Click here to add this to my saved trials
Los Angeles, California
Principal Investigator: Randolph Hecht, MD
Phone: 310-633-8400
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Newnan, Georgia 30265
Principal Investigator: Eyal Meiri, MD
Phone: 770-400-7191
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Park Ridge, Illinois 60068
Principal Investigator: Edward James, MD
Phone: 847-410-0667
Click here to add this to my saved trials
Pembroke Pines, Florida 33028
Principal Investigator: Pablo Ferraro, MD
Phone: 954-265-1864
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Redondo Beach, California 90277
Principal Investigator: Hugo Hool, MD
Phone: 310-750-3376
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Andrew Ko, MD
Phone: 415-353-7284
Click here to add this to my saved trials
Santa Barbara, California 93105
Principal Investigator: Gregg Newman, MD
Phone: 805-898-3602
Click here to add this to my saved trials
Santa Maria, California 93454
Principal Investigator: Robert Dichmann, MD
Phone: 805-346-3461
Click here to add this to my saved trials
Click here to add this to my saved trials
Spokane Valley, Washington 99216
Principal Investigator: Danko Martincic, MD
Phone: 509-228-1188
Click here to add this to my saved trials
Tulsa Cancer Institute, Pllc Now under the new name of Tulsa Cancer Institute, our specialists...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Worcester, Massachusetts 01608
Principal Investigator: James Rooney, MD
Phone: 508-556-5431
Click here to add this to my saved trials
Click here to add this to my saved trials